This inventor holds 2 USPTO granted patents. Top assignee: Korea Research Institute of Chemical Technology. Active years: 2020-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2026
Title: Mi-Sun Choi: Innovator in Liver Zonation Technology
Introduction
Mi-Sun Choi is a prominent inventor based in Daejeon, South Korea. She has made significant contributions to the field of biomedical engineering, particularly in the development of microfabricated platforms for liver research. Her innovative work aims to enhance the understanding of liver zonation and its implications for drug toxicity.
Latest Patents
Mi-Sun Choi holds a patent for a microfabricated platform designed to mimic liver zonation. The patent, titled "Microfabricated platform for mimicking the liver zonation and evaluating method of zonal toxicity using thereof," provides a method for evaluating zone-specific hepatotoxicity. This platform is divided into three zones, similar to in vivo liver tissue, allowing for a more accurate assessment of drug toxicity in different liver regions. The results can be quantitatively analyzed using image analysis, making it a valuable tool for in vitro screening of hepatotoxicity.
Career Highlights
Mi-Sun Choi is affiliated with the Korea Research Institute of Chemical Technology, where she continues to advance her research in liver zonation and toxicity evaluation. Her work has garnered attention for its potential applications in drug development and safety testing.
Collaborations
Mi-Sun Choi collaborates with notable colleagues, including Jung-Hwa Oh and Seokjoo Yoon, to further enhance the impact of her research. Their combined expertise contributes to the advancement of innovative solutions in the field.
Conclusion
Mi-Sun Choi's contributions to the field of liver zonation technology exemplify the importance of innovation in biomedical research. Her patented microfabricated platform represents a significant advancement in evaluating drug toxicity, paving the way for safer pharmaceutical development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
